XIAP

E3 ubiquitin-protein ligase XIAP

84,630 patent compounds predicted against XIAP, 47,753 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL40642	0.60	11/20
SCHEMBL159304	0.72	6/20
Embelin (SCHEMBL148744)	1.00	5/20
SCHEMBL157902	0.88	5/20
SCHEMBL157480	0.78	5/20
SCHEMBL157481	0.78	5/20
Hydrochloric Acid (SCHEMBL158501)	0.77	5/20
SCHEMBL158338	0.94	4/20
SCHEMBL158339	0.94	4/20
SCHEMBL156629	0.72	4/20
SCHEMBL172623	0.61	4/20
Ilepatril (SCHEMBL171139)	0.59	4/20
SCHEMBL159072	0.77	3/20
SCHEMBL157995	0.74	3/20
Hydrochloric Acid (SCHEMBL158745)	0.73	3/20
Hydrochloric Acid (SCHEMBL158746)	0.73	3/20
SCHEMBL158893	0.71	3/20
SCHEMBL156204	0.70	3/20
SCHEMBL175757	0.70	3/20
SCHEMBL175758	0.70	3/20

Germline variants in XIAP on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full XIAP gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to XIAP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)	PHASE1/PHASE2	COMPLETED
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer	PHASE2	COMPLETED
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma	PHASE2	WITHDRAWN
9-ING-41 in Patients With Advanced Cancers	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE2	RECRUITING
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)	PHASE1/PHASE2	WITHDRAWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies	PHASE1/PHASE2	COMPLETED
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	PHASE1	COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer	PHASE1	UNKNOWN
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma	nan	ACTIVE_NOT_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a XIAP binder may also engage these)

Protein	Name	Similarity
Q9R0I6	—	1.000	Q9R0I6 →
BIRC3	Baculoviral IAP repeat-containing protein 3	0.997	landscape →
Q60989	—	0.996	Q60989 →
Q95M71	—	0.994	Q95M71 →
BIRC2	Baculoviral IAP repeat-containing protein 2	0.994	landscape →
Q5BKL8	—	0.994	Q5BKL8 →
A5D8Q0	—	0.993	A5D8Q0 →
Q62210	—	0.993	Q62210 →
Q90660	—	0.993	Q90660 →
A1E2V0	—	0.992	A1E2V0 →
O08863	—	0.992	O08863 →
BIRC8	Baculoviral IAP repeat-containing protein 8	0.991	landscape →
Q95M72	—	0.989	Q95M72 →
O62640	—	0.988	O62640 →
Q24307	—	0.988	Q24307 →
P41435	—	0.981	P41435 →
Q6R7I2	—	0.981	Q6R7I2 →
G5EFA2	—	0.980	G5EFA2 →
Q6R7E2	—	0.979	Q6R7E2 →
P41454	—	0.979	P41454 →
Q24306	—	0.979	Q24306 →
Q3T9Z9	—	0.978	Q3T9Z9 →
B1B1A0	—	0.977	B1B1A0 →
Q19546	—	0.977	Q19546 →
Q9H0M0	—	0.977	Q9H0M0 →
Q8T3Y0	—	0.977	Q8T3Y0 →
O93530	—	0.977	O93530 →
Q14149	—	0.977	Q14149 →
Q9FT70	—	0.977	Q9FT70 →
Q96AP4	—	0.976	Q96AP4 →